
The Practice of Medicinal Chemistry
- 2nd Edition - June 11, 2003
- Imprint: Academic Press
- Editor: Camille Georges Wermuth
- Language: English
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 4 9 7 7 7 - 8
The Practice of Medicinal Chemistry, 2E, is a single-volume source on the practical aspects of medicinal chemistry. The successful first edition was nicknamed "The Bible" by medici… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quote- The only book available dealing with the practical aspects of medicinal chemistry
- Serves as a complete guide to the drug discovery process, from conception of the molecules to drug production
- Updated chapters devoted to the discovery of new lead compounds, including combinatorial chemistry
From Plant Extracts To DNA Technology
Medicinal Chemistry: Definition And Objectives, The Three Main Phases Of Drug Activity, Drug And Diseases Classifications
Measurement And Expression Of Drug Effects
Drug Targets: Molecular Mechanisms Of Drug Action
Strategies In The Search For New Lead Compounds Or Original Working Hypotheses
Natural Products As Pharmaceuticals And Sources For Lead Structures
Basics Of Combinatorial Chemistry
The Contribution Of Molecular Biology To Drug Discovery
Electronic Screening: Lead Finding From Database Mining
High-Speed Chemistry Libraries: Assessment Of Drug-Likeness
Web Alert — Using The Internet For Medicinal Chemistry
Molecular Variations In Homologous Series: Vinylogues And Benzologues
Molecular Variations Based On Isosteric Replacements
Ring Transformations
Introduction Of Conformational Restriction And/Or Steric Hindrance
Identical And Non Identical Twin Drugs
Optical Isomerism In Drugs
Application Strategies For The Primary Structure-Activity Relationship Exploration
Specific Substituent Groups
The Role Of Functional Groups In Drug-Receptor Interactions
Compound Properties And Drug Quality
Quantitative Approaches To Structure-Activity Relationships
Structural Aspects Of Drug Action I
Pharmacophore Identification And Receptor Mapping
Three-Dimentional Quantitative Structure-Property Relationships
Protein Crystallography And Drug Discovery
Protein Comparative Modelling And Drug Discovery
The Transition From Agonist To Antagonist Activity: Symmetry And Other Considerations
Design Of Peptidomimetics
The Fate Of Xenobiotics In Living Organisms
Biotransformation Reactions
Chemical Mechanisms Of Toxicity
Basic Knowledge For Designing Safer Drugs
Designing Prodrugs And Bioprecursors
Macromolecular Carriers For Drug Targeting
Preparation Of Water Soluble Compounds Through Salt Formation
Preparation Of Water-Soluble Compounds By Covalent Attachment Of Solubilizing Moieties
Drug Solubilization With Organic Solvents, Surfactants And Lipids
Improvement Of Drug Properties By Cyclodextrins
Chemical And Physicochemical Solutions To Formulation Problems
Discover A Drug Substance, Formulate And Develop It To A Product
Drug Nomenclature
Legal Aspects Of Product Protection
The Consumption And Production Of Pharmaceuticals
- Edition: 2
- Published: June 11, 2003
- Imprint: Academic Press
- No. of pages: 736
- Language: English
- eBook ISBN: 9780080497778
CW
Camille Georges Wermuth
Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d’Etudes Physio-biologiques Appliquées à la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine.
Professor Wermuths’ main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.
Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Société Française de Chimie Thérapeutique, the Léon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.